Goal 1. To develop an effective team of collaborators, with human resources as a key priority.
Growing our network of collaboration worldwide in the manner of cultivating connections within healthy brain neuronetworks.
Goal 2. To speak a common scientific idiom, through mutual agreements on the formulation of hypotheses, scientific ethics and obtaining evidence-based expertise.
Dialogue between basic and clinical neurosciences leading towards reliable treatment strategies and better treatment outcomes.
Goal 3. To manage meaningful projects in the domains of research & development, up-to-date paradigm of academic education, and clinical guidelines in neuropsychiatry, incorporating innovative technologies.
Teamwork focusing on research achievements, professional education, and improved quality of life of patients.
Epidemiology of mental disorders, stress-related environmental conditions, stress at work place, public health, mental health services, vulnerable population groups, children & adolescent mental health, Memory clinics and psychogeriatric services.
Women’s mental health, prevention of violence against women, and mental health in immigrant populations.
On-line calculators in early diagnosis of mental health disturbances (i.e. mixed affective states, depression, suicidality risk, anxiety, burnout).
Neuronetworks in remote recognition of affective disorders (depressions) via discovering facial mimic and speech patterns based on Machine Learning/Artificial Intelligence (ML/AI) approach.
Mental health, social and psychological well-being of the population during COVID-19 pandemic and associated lockdowns and in the context of vulnerable populations (general population, old age people, students, children and adolescents, patients with cardiovascular disorders, health professionals, etc.).
COVID-19-associated psychiatric and neurological complications (outpatients, in-patients with severe illness in COVID-hospitals, rare clinical cases, COVID-associated olfactory disorders).
Evidence-based and person-centered individualized psychoharmacotherapy of mental disorders.
Biotechnology and cell culture-based prediction test-systems, genetic and psychoneuroimmunological biomarkers of mental and behavioral disorders, psychopharmacogenetics and clinical trials of novel molecules in neuropsychiatry.
Virtual/Augmented reality (VR/AR) devices accompanied with biofeedback techniques as evidence-based novel approaches to treatment and interdisciplinary psychosocial rehabilitation of patients with mental, behavioural and neurological disorders (anxiety, depression, posttraumatic stress disorder, alcohol use disorder, burnout phenomenon, etc.).
Thought, language and communication disorder and social disadjustment in patients with schizophrenia spectrum disorders (i.e., cognitive endophenotypes of schizophrenia, and studies of patients and first-degree relatives).
Hereditary neurodegenerative diseases (Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, orphan neurological diseases).
Psycholinguistics and neurolinguistics of socially significant mental disorders (depression, schizophrenia, dementia, etc.).
Motor dysfunction, verbal fluency decline, disrupted embodied cognition, neurocognitive decline, social and emotional intelligence, and negative symptoms in schizophrenia spectrum disorders.
Intensive action language treatment (cognitive/language remediation techniques) in mental and neurological disorders.
